Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01840345 · ClinicalTrials.gov registry record · Phase 2
The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
A Phase 2 study of Neuropathic Pain, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01840345: Completed Phase 2 study of Neuropathic Pain, sponsored by Virginia Commonwealth University.
NCT01840345 is a Phase 2 study of Neuropathic Pain that has completed, run by Virginia Commonwealth University. The registered enrollment target is 11 participants, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01840345, a Phase 2 study of Neuropathic Pain, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.
Primary Outcome
The amount of opioid medication used was recorded. Then, it was converted to morphine equivalents (https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Opioid-Morphine-EQ-Conversion-Factors-March-2015.pdf). Opioid use was measured over a 2-week baseline period. Then, the average opioid medication use/week was calculated. This was compared to the average opioid medication use/week after 4 weeks of NAC.
Conditions Studied
Interventions
- DRUG N-acetyl-l-cysteine
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-01 |
| Est. Completion | 2017-04-01 |
| Phase | Phase 2 |
What the finished NCT01840345 record still lists
NCT01840345 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 101-participant average among 35 other Neuropathic Pain trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Neuropathic Pain appearing as the primary indexed condition, and to 1 intervention - of which N-acetyl-l-cysteine is the first listed.
NCT01840345 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT01840345 about?
NCT01840345 is a clinical study titled "The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain". This study will test whether treatment with N-acetyl-L-cysteine (NAC) is safe and decreases pain in patients with chronic neuropathic pain. The investigators hypothesize that NAC will be a useful adjunct to opioid treatment in chronic neuropathic pain.
What is the current status of trial NCT01840345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2014-01. Estimated completion is 2017-04-01.
What conditions does trial NCT01840345 study?
This clinical trial studies the following conditions: Neuropathic Pain.
What interventions are being tested in trial NCT01840345?
The interventions under investigation include: N-acetyl-l-cysteine (DRUG).
Who is sponsoring clinical trial NCT01840345?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01840345 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01840345's enrollment target sits among peer trials
11 35th of 35 higher than 1 of 35 other Neuropathic Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuropathic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy
RECRUITING · Phase 2
-
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
RECRUITING · Phase 2
-
Ginger Root Extract for Sciatic Pain Individuals
RECRUITING · Phase 2
-
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Interventions For Pain Induced By Vincristine Treatment For Childhood Acute Lymphoblastic Leukemia (ALL)
COMPLETED · Phase 2
-
BMS-741672 for Diabetic Neuropathic Pain
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia